Interleukin-13 (IL-13) receptor alpha2 (IL-13Ralpha2), a high-affinity
IL-13 binding subunit and a
tumor antigen, is amplified in a variety of human tumor cell lines and
tumors in vivo. By
cDNA microarray, we have shown that gene transfer of human and rat
adrenomedullin (AM) up-regulates IL-13Ralpha2 in a human prostate tumor cell line. Here, we show that IL-13Ralpha2
mRNA and
protein are also up-regulated in PC-3 prostate
tumor cells by recombinant AM (rAM) and human synthetic AM
peptide in a dose-dependent manner in vitro and in vivo in mouse prostate
tumor model. The 8- to 10-fold up-regulation of IL-13Ralpha2 by rAM or AM
peptide in prostate
tumor cells in vitro and in vivo increased their sensitivity to IL-13PE
cytotoxin consisting of
IL-13 and a truncated form of Pseudomonas
exotoxin. Immunodeficient mice with established prostate
tumors transfected with AM or treated with AM
peptide showed reduction in
tumor size by intratumoral administration of IL-13PE in a dose-dependent manner. At the highest dose (three 100 mug/kg/d every alternate day), >70% reduction of
tumor size was observed compared with controls (P <or= 0.01). These results indicate that two completely unrelated
hormones (AM and
IL-13) are closely related to each other and that we have identified a novel role of AM in sensitizing certain types of prostate
tumors to IL-13R-directed therapeutic agent.